Table 2.
Number of inpatient and outpatient immune checkpoint inhibitor treatment–associated irAEs by irAE type
| irAE type | Total events, n | Inpatient n (%) | Outpatient n (%) |
|---|---|---|---|
| Lung/hematologic/cardiovascular | |||
| Acquired hemophilia | 1 | 0 (0) | 1 (100) |
| Arrhythmia | 192 | 102 (53) | 90 (47) |
| Anemia | 1,717 | 936 (55) | 781 (45) |
| Hemolytic anemia | 13 | 4 (31) | 9 (69) |
| Impaired ventricular function with heart failure and vasculitis | 1,285 | 830 (65) | 455 (35) |
| Myocarditis | 4 | 4 (100) | 0 (0) |
| Pericarditis | 18 | 11 (61) | 7 (39) |
| Pneumonitis | 10 | 5 (50) | 5 (50) |
| Thrombocytopenia | 1,069 | 555 (52) | 514 (48) |
| Venous thromboembolism | 678 | 387 (57) | 291 (43) |
| Endocrine | |||
| Adrenal insufficiency | 325 | 42 (13) | 283 (87) |
| Diabetes | 87 | 27 (31) | 60 (69) |
| Pituitary | 180 | 128 (71) | 52 (29) |
| Thyroid | 1,568 | 366 (23) | 1,202 (77) |
| Musculoskeletal/neurological | |||
| Encephalitis | 10 | 8 (80) | 2 (20) |
| Guillain‐Barré syndrome | 2 | 1 (50) | 1 (50) |
| Inflammatory arthritis | 343 | 76 (22) | 267 (78) |
| Myositis | 13 | 8 (62) | 5 (38) |
| Peripheral or autonomic neuropathy | 890 | 245 (28) | 645 (72) |
| Polymyalgia‐like syndrome | 21 | 2 (10) | 19 (90) |
| Transverse myelitis | 5 | 5 (100) | 0 (0) |
| Gastrointestinal/kidney | |||
| Colitis | 384 | 223 (58) | 161 (42) |
| Hepatitis | 81 | 45 (56) | 36 (44) |
| Nephritis | 97 | 64 (66) | 33 (34) |
| Dermatologic | |||
| Stevens‐Johnson syndrome | 8 | 1 (13) | 7 (88) |
| Toxic epidermal necrolysis | 1 | 1 (100) | 0 (0) |
| Other | |||
| Blepharitis | 7 | 3 (43) | 4 (57) |
| Peripheral edema | 1,112 | 165 (15) | 947 (85) |
| Totals | 10,121 | 4,244 (42) | 5,877 (58) |
Abbreviation: irAE, immune‐related adverse event.